ABT - Abbott Laboratories
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 102.14 |
| Open | 102.15 |
| Bid | 101.69 x 1000 |
| Ask | 103.03 x 1100 |
| Day's Range | 102.07 - 103.45 |
| 52 Week Range | 93.25 - 118.23 |
| Volume | |
| Avg. Volume | 5,173,325 |
| Market Cap | 178.886B |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | 31.27 |
| EPS (TTM) | 3.29 |
| Earnings Date | Jul 18, 2023 - Jul 24, 2023 |
| Forward Dividend & Yield | 2.04 (1.98%) |
| Ex-Dividend Date | Apr 13, 2023 |
| 1y Target Est | 124.90 |
Fair Value
Related Research
ZacksAbbott (ABT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
InvestopediaFTC Investigates Abbott For Alleged Collusion in Federal Baby Formula Contract Bids
Abbott, the nation’s largest maker of infant formula, is being investigated by the Federal Trade Commission for potentially anti-competitive federal nutrition program bids.
ZacksAbbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
- Financial Times
Infant formula producers probed by FTC over bids for government contracts
Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families
BenzingaIs There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
The Federal Trade Commission's (FTC) investigation concerns potential collusion among baby-formula manufacturers as it examines whether companies like Abbott Laboratories (NYSE: ABT) and other formula manufacturers have engaged in collusion or coordination while bidding for state contracts. Furthermore, the agency is also exploring whether the coordination among these companies has had a broader impact on sales outside of the Women, Infants, and Children (WIC) formula-supply program, as stated b
Yahoo Finance VideoFTC investigating baby-formula makers on suspected collusion
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
The Wall Street JournalBaby-Formula Makers Face FTC Investigation for Collusion
The agency is investigating whether any formula manufacturers coordinated before bidding for state contracts.
PR NewswireEuropean Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy (GDMT). G
Fox BusinessFTC probing Abbott, other baby-formula makers for collusion
Regulators are reportedly investigating whether the companies that produce baby-formula colluded on bids for lucrative state contracts.
ReutersUPDATE 3-Abbott, baby formula makers face FTC probe for potential collusion
The U.S. Federal Trade Commission (FTC) is probing whether Abbott Laboratories and other companies that make baby formula colluded in bidding on state contracts, according to a document posted on the agency's website. The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe.
ReutersAbbott, baby formula makers face FTC probe for potential collusion
The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe. According to the document, in 2022 the FTC began looking into potential collusion or coordination in bids to provide formula for the U.S. Department of Agriculture's Women, Infants and Children (WIC) program that provides free formula to low-income families.
BenzingaAbbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had a "substantial risk" of bacteria contamination. The parents said they would not have bought or paid less for formula but for the company's claims that it was safe. Related: Republicans Seek Documents, Schedule Hearing Related To FDA's Response To Baby-Formula Shortage. Last February, Abbott recall
- Reuters
UPDATE 1-Judge tosses out some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
ReutersJudge tosses out some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
- Reuters
Judge tosses some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The parents said they would not have bought or would have paid less for formula but for the Abbott Park, Illinois-based company's claims that it was safe.
ZacksAbbott (ABT) Expands in Electrophysiology With New FDA Nod
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
PR NewswireAbbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for people with slower-than-normal heart rhythms.
BenzingaStereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months. Concurr
- Zacks
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
ZacksAbbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACCESSWIREComing Together on the Journey to End Parkinson’s
As far as epic journeys go, 1.2 miles is pretty manageable and quite lovely.
PR NewswireAbbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible tip and contact force technology.
PR NewswireAbbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.
TipRanksBillionaire Paul Tudor Jones Pours Millions Into These 2 Stocks Amid Recession Fears
The assumption among most financial prognosticators is that a recession is most likely on the way, and one prominent name agrees it’s all but inevitable. Legendary investor Paul Tudor Jones sees a recession coming and even has an idea of when it will hit. The Tudor Investment Corp founder and billionaire expects a recession will come into play this fall, mainly as a result of the surge in debt and asset prices in recent years. Such activities are usually followed by an economic downturn. “Histor
Insider MonkeyBillionaire Ray Dalio’s Top 12 Dividend Stock Picks
In this article, we will take a look at billionaire Ray Dalio’s top 12 stock picks. You can skip our detailed analysis of Ray Dalio’s hedge fund and recent developments, and go directly to read Billionaire Ray Dalio’s Top 5 Dividend Stock Picks. Ray Dalio founded Bridgewater Associates in 1975. Today, it is one of […]